Jiang Wei, Zhang Bo, Xu Jiaqi, Xue Liyan, Wang Luhua
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, P. R. China.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Cancer Commun (Lond). 2025 Mar;45(3):281-331. doi: 10.1002/cac2.12645. Epub 2024 Dec 26.
Esophageal cancer (EC) continues to be a significant global health concern, with two main subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevention and changes in etiology, improvements in early detection, and refinements in the treatment have led to remarkable progress in the outcomes of EC patients in the past two decades. This seminar provides an in-depth analysis of advances in the epidemiology, disease biology, screening, diagnosis, and treatment landscape of esophageal cancer, focusing on the ongoing debate surrounding multimodality therapy. Despite significant advancements, EC remains a deadly disease, underscoring the need for continued research into early detection methods, understanding the molecular mechanisms, and developing effective treatments.
食管癌(EC)仍然是一个重大的全球健康问题,主要有两种亚型:食管鳞状细胞癌和食管腺癌。在过去二十年中,病因学方面的预防与变化、早期检测的改善以及治疗方法的优化,使得食管癌患者的治疗效果取得了显著进展。本次研讨会对食管癌的流行病学、疾病生物学、筛查、诊断和治疗领域的进展进行了深入分析,重点关注围绕多模式治疗的持续争论。尽管取得了重大进展,但食管癌仍然是一种致命疾病,这突出表明需要继续研究早期检测方法、了解分子机制并开发有效的治疗方法。